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Context: The polycystic ovary syndrome (PCOS) is frequently asso-
ciated with visceral obesity, suggesting that omental adipose tissue
might play an important role in the pathogenesis of the syndrome.
Objective:The objective was to study the expression profiles of omental
fat biopsy samples obtained from morbidly obese women with or without
PCOS at the time of bariatric surgery.
Design: This was a case-control study.
Settings: We conducted the study in an academic hospital.
Patients: Eight PCOS patients and seven nonhyperandrogenic
women submitted to bariatric surgery because of morbid obesity.
Interventions: Biopsy samples of omental fat were obtained during
bariatric surgery.
Main Outcome Measure: The main outcome measure was high-
density oligonucleotide arrays.
Results: After statistical analysis, we identified changes in the ex-
pression patterns of 63 genes between PCOS and control samples.
Gene classification was assessed through data mining of Gene
Ontology annotations and cluster analysis of dysregulated genes
between both groups. These methods highlighted abnormal ex-
pression of genes encoding certain components of several biological
pathways related to insulin signaling and Wnt signaling, oxidative
stress, inflammation, immune function, and lipid metabolism, as
well as other genes previously related to PCOS or to the metabolic
syndrome.
Conclusion: The differences in the gene expression profiles in vis-
ceral adipose tissue of PCOS patients compared with nonhyperan-
drogenic women involve multiple genes related to several biological
pathways, suggesting that the involvement of abdominal obesity in
the pathogenesis of PCOS is more ample than previously thought and
is not restricted to the induction of insulin resistance. (J Clin En-
docrinol Metab 92: 328–337, 2007)
THE POLYCYSTIC OVARY syndrome (PCOS) appears tobe a complex disorder in terms of inheritance, in which
protective and predisposing genomic variants interfere with
a very important environmental influence, including diet
and lifestyle, leading to the syndrome’s phenotype (1).
Obesity plays a very important role in the development of
PCOS in many women. PCOS patients are frequently obese
(2); as many as 42% of women with PCOS were overweight
or obese in population-based studies conducted in the
United States (3). Conversely, PCOS is probably the most
common association of obesity in premenopausal women,
because 28% of overweight and obese women have this prev-
alent disorder (4). This association may be explained by the
secretion by adipose tissue of several mediators, including
cytokines and adipokines, that favor the insulin resistant and
low-grade chronic inflammatory state characteristic of PCOS
(1, 5–7).
The hyperandrogenism characteristic of PCOS also may
influence the pathophysiology of obesity. Androgen excess
during fetal life or during the early postnatal period induced
abdominal adiposity and an adverse metabolic profile in
animal models (8), and a similar mechanism might occur in
humans (9). Furthermore, girls with premature pubarche—a
form of prepubertal hyperandrogenism that predisposes
these girls to PCOS—have insulin resistance throughout pu-
berty (10), and treatment with antiandrogens may contribute
to ameliorate the insulin resistance of these girls (11). There-
fore, the possibility exists that women with PCOS have a
vicious circle that starts with hyperandrogenism favoring an
abdominal visceral deposition of fat that induces insulin
resistance, and the resulting hyperinsulinemia further facil-
itates androgen secretion in these patients (12).
Given the central role of visceral adipose tissue in the
development of PCOS in overweight and obese women, we
have considered of interest the study of the expression pro-
files of omental fat biopsy samples obtained from morbidly
obese women with or without PCOS at the time of bariatric
surgery. Compared with classic molecular genetic ap-
First Published Online October 24, 2006
Abbreviations: BMI, Body mass index; GO, gene ontology; HOMA-
IR, homeostasis model assessment for insulin resistance; FOXA2, fork-
head box A2; IR, insulin receptor; PCOS, polycystic ovary syndrome;
qPCR, quantitative PCR; RMA, robust multi-array analysis; SAM, sig-
nificance analysis of microarrays; TFBS, transcription factor binding site;
TransFAT, Transcription Factor Association Test tool.
JCEM is published monthly by The Endocrine Society (http://www.
endo-society.org), the foremost professional society serving the en-
docrine community.
0021-972X/07/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 92(1):328–337
Printed in U.S.A. Copyright © 2007 by The Endocrine Society
doi: 10.1210/jc.2006-1665
328
 by on May 28, 2010 jcem.endojournals.orgDownloaded from 
proaches, our present experimental design had the theoret-
ical advantages of using a hypothesis-free approach to find
genes dysregulated in the visceral fat of PCOS patients, as
well as providing an integrative view of the interaction of
genomic variants with environmental influences that result
in gene expression in adipose tissue.
Subjects and Methods
Subjects, sampling, and surgical procedure
Fifteen morbidly obese premenopausal women submitted for bari-
atric surgery, including eight PCOS patients [age 31.6  7.9 yr; body
mass index (BMI) 51.0  10.2 kg/m2, range 41–75 kg/m2] and seven
nonhyperandrogenic women (age 40.4  3.6 yr; BMI 52.8  5 kg/m2,
range 44–58 kg/m2) were included. The study was conducted according
to the Declaration of Helsinki and was approved by the ethics committee
of Hospital Ramo´n y Cajal. Signed informed consent was obtained from
all subjects.
The diagnosis of PCOS was established by the presence of oligoovu-
lation, clinical and/or biochemical hyperandrogenism, and exclusion of
hyperprolactinemia, nonclassic congenital adrenal hyperplasia, and an-
drogen-secreting tumors (13). Hirsutism was quantified by the modified
Ferriman-Gallwey score (14). Evidence for oligoovulation was provided
by chronic oligomenorrhea or amenorrhea in all the patients. The con-
trols had no signs of hyperandrogenism and had regular menstrual
cycles every 26–34 d. None of the patients and controls were being
treated with insulin sensitizers, statins, or hormonal therapy.
After a 12-h overnight fast, basal blood samples were obtained for the
measurement of serum glucose, insulin, prolactin, total testosterone,
SHBG, 17-hydroxyprogesterone, androstenedione, and dehydroepi-
androsterone-sulfate. The technical characteristics of the assays used for
hormone measurements have been reported elsewhere (15). The free
testosterone concentration was calculated from total testosterone and
SHBG concentrations (16). Insulin resistance in the fasting state was
determined using homeostasis model assessment (HOMA-IR) (17).
The indication for bariatric surgery was morbid obesity in all patients,
as defined by BMI 40 kg/m2 or greater (18). During surgery, biopsy
samples of omental fat were obtained, washed in chilled NaCl 0.9%
solution, partitioned into pieces, and immediately frozen in liquid ni-
trogen and stored at 80 C until total RNA preparation. The surgeon
aimed to obtain the samples from similar anatomical locations in all the
women, and patients and controls were submitted to the same anesthetic
procedures to avoid a potential effect on the expression of susceptible
genes such as those related to stress and inflammation.
RNA isolation, array hybridization, and data processing
Total RNA was extracted from omental adipose tissue (500 mg) using
Trizol (Invitrogen Corp., Carlsbad, CA), followed by the QIAGEN
RNeasy kit (QIAGEN N.V., Venlo, The Netherlands), and was tested for
degradation using the Agilent 2100 Bioanalyzer (Agilent Technologies,
Inc., Palo Alto, CA). cDNA was synthesized from 5 g total RNA using
T7-(dT)24 oligonucleotide (Superscript II Reverse Transcriptase; Invitro-
gen Corp.). In vitro transcription was performed using BioArray High
Yield RNA transcript labeling kit (Enzo Life Sciences, Inc., Farmingdale,
NY) to produce biotin labeled cRNA; 5 g fragmented cRNA was used
for the TestChip (Test3; Affymetrix, Inc., Santa Clara, CA). After quality-
control, 15 g cRNA was hybridized for 16 h at 45 C to the Affymetrix
HG-U133A chip. Each microarray was washed and stained in the Af-
fymetrix Fluidics Station 400 following the standard protocols. Microar-
rays were scanned at 3-m resolution in an Agilent HP G2500A Gene-
Array scanner. A very high experimental reproducibility (r2  0.97), as
assessed by hybridizing two arrays with RNA from the same sample,
was found. Furthermore, the concordance of the results of pairs of arrays
hybridized using RNA from different women was also high (0.97  r2
 0.84), indicating low interindividual variability in the gene expression
of omental fat.
Data analyses were performed using Affymetrix Microarray Suite 5.0
software and images from each gene chip were normalized by the global
scaling method to a target intensity value of 100, following the manu-
facturer’s instructions. Also we used the robust multiarray analysis
(RMA) algorithm for normalization, by applying the RMA Express soft-
ware (19). To reduce the complexity of data, the expression analysis was
restricted to a subset of reproducibly expressed probe sets that signif-
icantly varied among the data. Probe sets with “absent calls” across all
samples and/or absolute fold change less than 1.2 were filtered out.
Complete data sets are available from the National Center for Biotech-
nology Information Gene Expression Omnibus web site, accession no.
GSE5090.
Quantitative RT-PCR
Reverse transcription (RT) was performed using 1g total RNA, with
random hexamers and the High-Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA). Quantitative PCR (qPCR) was performed
in the ABI Prism 7900HT using specific primers and probes for target
genes (TaqMan Low-Density Array System; Applied Biosystems). cD-
NAs were diluted to a final concentration of 0.5 ng/l and incubated at
95 C for 10 min followed by 40 cycles (15 sec at 95 C and 1 min at 60 C).
Glyceraldehyde-3-phosphate dehydrogenase, peptidylprolyl isomerase
A, and glucuronidase  were included in the qPCR as endogenous
controls. Fluorescence intensity was recorded by using ABI 7700 Prism
SDS 2.1 software (Applied Biosystems), and the results were plotted vs.
cycle number. The Ct method was used to calculate relative changes
in mRNA abundance as fold change values (20).
Statistical analysis
The differences in clinical and hormonal variables between PCOS
patients and nonhyperandrogenic controls were evaluated by the Mann-
Whitney U test. The differential gene expression was evaluated by using
a two-tail unequal-variances t test implemented in the Gene Expression
Pattern Analysis Suite package (21). Also, a permutation-based statis-
tical method termed significance analysis of microarrays (SAM) was
achieved in a two-unpaired classes format, which performs a correction
for multiple testing using the false discovery rate method (22). Anno-
tations of PCOS dysregulated probe sets were collected from different
available databases by using the NetAffx online tool (http://www.af-
fymetrix.com/analysis/index.affx), and their identity was verified us-
ing the BLAST tool (http://www.ncbi.nlm.nih.gov).
The sequence of the promoter region (from 1000 to  100 bp with
respect to the start of transcription site) for each dysregulated gene was
obtained from the Transcriptional Regulatory Element Database
(http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?processhome). A
search for androgen response elements in these regions was conducted
using the MatInspector software (23), using the V$ARE.01 and
V$ARE.02 matrixes contained in the MatBase version 6.1 library (Geno-
matix Software GmbH, Mu¨nchen, Germany). Spearman’s nonparamet-
ric correlation analysis and partial correlation analysis were used to
study the influence of age, hyperandrogenism, and insulin resistance on
gene expression as described.
Functional analysis was performed on the basis of gene ontology
(GO) terms by using Onto-Express Tool (24). Significantly overrepre-
sented or underrepresented GO terms among the differentially ex-
pressed dataset were obtained in relation to the number of probe sets
expected for each GO category, based on their representation on the
Affymetrix U133A array. A 2 test was performed to determine confi-
dence levels for differential expression within ontology groups, and the
P values were corrected for multiple testing based in the false discovery
rate method.
Genesis software (http://genome.tugraz.at) was used for hierarchi-
cal clustering analysis of PCOS-regulated genes applying average link-
age and Pearson’s correlation as a measure of similarity.
The Transcription Factor Association Test tool (TransFAT) (25) was
used to detect under- or overrepresentation of putative transcription
factor binding sites (TFBSs) in coexpressed genes. Each gene cluster
obtained by clustering analysis was compared against the rest of the
altered PCOS genes. TFBSs were searched in the 10-kb upstream region
of the selected genes by using Match program. Only TransFAT high-
quality matrices were used with a cutoff to minimize false positives.
Finally, a Fisher’s exact test was performed to obtain significant TFBSs
overrepresentation in the cluster we were analyzing. For RT-qPCR anal-
yses, the Mann-Whitney U test was used. Statistical significance was set
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at the P 0.05 level for all analyses except when correcting for multiple
testing.
Results
Description of PCOS patients and
nonhyperandrogenic controls
The comparisons of clinical, biochemical, and hormonal
variables between PCOS patients and controls are shown in
Table 1. PCOS patients were younger and presented with
statistically significant increases in hirsutism scores and free
testosterone levels, and decreased SHBG concentrations,
compared with nonhyperandrogenic controls. No other dif-
ferences were found, although indexes of insulin resistance
such as fasting insulin and HOMA-IR showed median values
that were close to twice as high in PCOS patients compared
with nonhyperandrogenic controls. PCOS patients and con-
trols presented metabolic comorbidities with similar
frequencies.
Identification of differentially expressed genes between
PCOS patients and nonhyperandrogenic women
After removing the noninformative probe sets from the
analysis, 3,055 of the 22,284 transcripts evaluated on the
Affymetrix HG-U133A chip were subsequently analyzed.
Microarray data were analyzed by an uncorrected two-tail
standard t test after normalization by the MAS5.0 and RMA
algorithms and showed that 391 probe sets were differen-
tially expressed between PCOS patients and nonhyperan-
drogenic women.
To control for multiple testing, we applied the more strict
SAM procedure, using an estimated false discovery rate of
0.5%, and 78 of the 391 dysregulated probe sets retained
statistical significance. These probe sets exhibited differential
gene expression 1.5-fold or greater. Often more than one
probe set detected a similar change in the same gene, pro-
viding additional validation of the expression data (Tables 2
and 3).
Of the 78 probe sets, 42 of them, representing 39 genes,
were overexpressed in PCOS patients compared with the
nonhyperandrogenic women (Table 2), whereas 36 probe
sets, representing 24 genes, were underexpressed (Table 3).
To confirm the gene expression pattern by an independent
method, we performed RT-qPCR for 50 genes. We found a
close correlation between microarray and real-time PCR
data, and the differential expression was confirmed for most
genes. Figure 1 shows the comparison of gene expression by
both methods for 12 genes.
Influence of age, hyperandrogenism, and insulin resistance
on gene expression
Because patients were younger than controls, we studied
the correlation of age and the levels of expression of the 63
genes described, including PCOS patients and nonhyperan-
drogenic women as a whole. Age showed significant corre-
lations with the expression of CHI3L1 (r  0.59, P  0.021),
CLIC5 (r  0.63, P  0.012), JARID1A (r  0.66, P 
0.007), NRID2 (r  0.66, P  0.008), SCD (r  0.62, P 
0.014), TCF4 (r0.64, P 0.011), and SERINC3 (r0.62,
P  0.015), suggesting that the up-regulation or down-reg-
ulation of these genes seen in PCOS samples might result
from the younger age of the patients.
Furthermore, the dysregulation of gene expression in the
omental tissue of PCOS patients may be a consequence of
hyperandrogenism or may also play a causative role in the
insulin resistance characteristic of the syndrome. Of note,
several of the genes dysregulated in the omental fat of our
TABLE 1. Clinical and biochemical characteristics of PCOS patients and controls
Controls (n  7) PCOS patients (n  8) P value
Waist to hip ratio 0.84 (0.10) 0.77 (0.09) 0.281
Hirsutism score 2 (3) 9 (12) 0.004
Systolic blood pressure (mm Hg) 130 (20) 130 (0) 0.902
Diastolic blood pressure (mm Hg) 70 (20) 80 (15) 0.456
Total cholesterol (mg/dl) 180 (43) 178 (74) 0.779
High-density lipoprotein cholesterol (mg/dl) 49 (16) 37 (10) 0.072
Low-density lipoprotein cholesterol (mg/dl) 110 (32) 113 (41) 0.536
Triglycerides (mg/dl) 104 (52) 123 (66) 0.463
Total testosterone (ng/dl) 46 (31) 76 (54) 0.336
Free testosterone (ng/dl) 1.0 (0.5) 1.6 (1.1) 0.040
SHBG (g/dL) 325 (124) 161 (146) 0.009
Dehydroepiandrosterone-sulfate (ng/ml) 982 (1159) 1330 (1630) 0.128
17-Hydroxyprogesterone (ng/ml) 0.8 (1.0) 0.8 (0.5) 0.535
Androstenedione (ng/ml) 2.0 (0.7) 4.0 (3.7) 0.053
Fasting glucose (mg/dl) 90 (17) 95 (4) 0.281
Fasting insulin (UI/ml) 11.8 (17.8) 23.8 (25.6) 0.121
Glucose/insulin ratio 0.06 (0.03) 0.03 (0.03) 0.094
Insulin resistance (HOMA-IR) 2.8 (8.0) 5.4 (6.6) 0.232
Dyslipidemia 1 (14%) 0 (0%) 0.467
Hypertension 3 (43%) 2 (25%) 0.326
Impaired fasting glucose 1 (14%) 0 (0%) 0.467
Type 2 diabetes 0 (0%) 0 (0%) 1.000
Data are medians (interquartile range) or raw numbers (percentage) for continuous and discontinuous variables, respectively. To convert
to SI units, multiply cholesterol by 0.0259 (resulting in mmol/liter), triglycerides by 0.0113 (resulting in mmol/liter), total testosterone by 0.03467
(resulting in nmol/liter), free testosterone by 34.67 (resulting in pmol/liter), SHBG by 0.111 (resulting in nmol/liter), dehydroepiandrosterone-
sulfate by 0.002714 (resulting in mol/liter), 17-hydroxyprogesterone by 3.026 (resulting in nmol/liter), androstenedione by 3.49 (resulting in
nmol/liter), glucose by 0.0555 (resulting by mmol/liter), and insulin by 6.945 (resulting in pmol/liter).
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PCOS patients contained putative androgen response ele-
ments in their promoters (Table 4). Therefore, we studied the
correlations between the levels of expression of the 63 genes
with free testosterone as an index of hyperandrogenism and
with HOMA-IR as an index of insulin resistance. Free tes-
tosterone levels correlated with the expression of ACTG2
(r  0.60, P  0.017), EBF2 (r  0.57, P  0.027),
HLA_DQ1A (r  0.61, P  0.016), JARID1A (r  0.57, P 
0.027), RHOQ (r  0.65, P  0.009), and SERINC3 (r  0.64,
P  0.011), whereas insulin resistance correlated with SCD
expression (r  0.53, P  0.043). However, the expression of
JARID1A, SERINC3, and SCD correlated also with age as
described. After correcting the influence of age by partial
correlation analysis, the correlations of JARID1A and
SERINC3 with free testosterone, and that of SCD with insulin
resistance, did not retain statistical significance (r 0.38, P
0.183; r  0.51, P  0.064; and r  0.093, P  0.750, respec-
tively). Therefore, only hyperandrogenism, and not insulin
resistance, correlated with the expression of a few genes
(ACTG2, EBF2, HLA_DQ1A, and RHOQ) in our model.
Nevertheless, because 63 separate correlation analyses
were performed for each independent variable, it must be
highlighted that none of the correlations described retained
statistical significance after applying a Bonferroni correction
for multiple testing to the level of significance (decreasing it
to P  0.00079), casting doubt on the actual relevance of all
these correlations.
Classification of dysregulated genes according to gene
ontology categories
Genes with altered expression in PCOS phenotype were
subsequently classified into GO categories. The 2 test re-
vealed significant ontology groups that were differentially
TABLE 2. Up-regulated gene transcripts in PCOS patients compared with nonhyperandrogenic subjects
Affymetrix
probe set Gene name Gene symbol
Fold
change Function
205969_at Arylacetamide deacetylase (esterase) AADAC 1.80 Lipid metabolism
207328_at Arachidonate 15-lipoxygenase ALOX15 1.66 Lipid metabolism
209788_s_at Type 1 tumor necrosis factor receptor shedding aminopeptidase ARTS-1 2.23 Fat cell differentiation
219866_at Chloride intracellular channel 5 CLIC5 1.51 Chloride transport
213998_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 DDX17 1.61 RNA helicase
219237_s_at DnaJ (HSP40) homolog, subfamily B member 14 DNAJB14 1.68 Response to stress
220392_at Early B-cell factor 2 EBF2 1.72 Transcription
201693_s_at Early growth response 1 EGR1 1.51 Transcription
205066_s_at Ectonucleotide pyrophosphatase/phosphodiesterase 1 ENPP1 1.70 Insulin signaling
206404_at Fibroblast growth factor 9 (glia-activating factor) FGF9 1.54 Growth factor activity
219054_at Hypothetical protein FLJ14054 FLJ14054 1.73
204358_s_at Fibronectin leucine rich transmembrane protein 2 FLRT2 1.67 Receptor signaling
219250_s_at Fibronectin leucine rich transmembrane protein 3 FLRT3 1.57 Receptor signaling
202554_s_at Glutathione S-transferase M3 GSTM3 1.71 Detoxification
213831_at Major histocompatibility complex, class II, DQ  1 HLA-DQA1 2.09 Immune response
205404_at Hydroxysteroid (11-) dehydrogenase 1 HSD11B1 1.50 Steroid metabolism
215698_at Jumonji, AT rich interactive domain 1A (RBBP2-like) JARID1A 2.05 Transcription
202040_s_at Jumonji, AT rich interactive domain 1A (RBBP2-like) JARID1A 1.58 Transcription
207092_at Leptin (obesity homolog, mouse) LEP 1.50 Energy metabolism
219759_at Leukocyte-derived arginine aminopeptidase LRAP 1.55 Antigen processing
213764_s_at Microfibrillar associated protein 5 MFAP5 1.72 Extracellular matrix
structural constituent
213765_at Microfibrillar associated protein 5 MFAP5 1.66 Extracellular matrix
219789_at Natriuretic peptide receptor C/guanylate cyclase C NPR3 2.25 Peptide receptor activity
201467_s_at NAD(P)H dehydrogenase, quinone 1 NQO1 1.78 Detoxification
201468_s_at NAD(P)H dehydrogenase, quinone 1 NQO1 1.78 Detoxification
209750_at Nuclear receptor subfamily 1, group D, member 2 NR1D2 1.51 Steroid hormone receptor
214680_at Neurotrophic tyrosine kinase, receptor, type 2 NTRK2 1.60 Neurotrophin receptor
203803_at Prenylcysteine oxidase 1 PCYOX1 1.51 Prenylcysteine metabolism
222317_at Phosphodiesterase 3B, cGMP-inhibited PDE3B 1.52 Insulin signaling
212249_at Phosphoinositide-3-kinase, regulatory subunit, polypeptide 1
(p85)
PIK3R1 1.61 Insulin signaling
212629_s_at Protein kinase C-like 2 PKN2 1.70 Signal transduction
214449_s_at Ras homolog gene family, member Q RHOQ 1.63 Insulin signaling
200832_s_at Stearoyl-CoA desaturase (-9-desaturase) SCD 1.61 Fatty acid biosynthesis
221473_x_at Serine incorporator 3 SERINC3 1.62
207057_at Solute carrier family 16 (monocarboxylic acid transporters),
member 7
SLC16A7 1.61 Pyruvate transport
221276_s_at Intermediate filament protein syncoilin SYNC1 1.52 Structural protein
218930_s_at Transmembrane protein 106B TMEM106B 1.51
212382_at Transcription factor 4 TCF4 1.67 Transcription
204731_at Transforming growth factor,  receptor III (betaglycan) TGFBR3 1.61 TGF signaling
221496_s_at Transducer of ERBB2, 2 TOB2 1.96 Cell proliferation
201387_s_at Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) UCHL1 1.51 Protein deubiquitination
206658_at Uroplakin 3B UPK3B 1.74
Fold change values were obtained by the SAM test.
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represented in PCOS-dysregulated genes. As shown in Table
5, several of the significantly overrepresented GO terms in
PCOS patients compared with controls were related to ox-
idoreductase activity and toxicity including response to
toxin, nicotinamide adenine dinucleotide (phosphate) dehy-
drogenase (quinone) activity, and oxidoreductase activity.
GO terms related to cell adhesion, cell recognition, and de-
fense response were significantly represented, yet to a lesser
extent, in PCOS samples.
Searching for gene expression patterns
To study the regulatory relationships among dysregulated
genes in PCOS, we conducted hierarchical clustering anal-
ysis based on their expression profiles. As shown in Fig. 2,
coexpressed genes were clustered into two main branches,
one of overexpressed genes (six clusters) and another of
underexpressed genes four clusters). Different Affymetrix
probe sets for the same gene, as well as functionally related
TABLE 3. Down-regulated gene transcripts in PCOS patients compared with nonhyperandrogenic subjects
Affymetrix
probe set Gene name
Gene
symbol
Fold
change Function
200974_at Actin,  2, smooth muscle, aorta ACTA2 0.60 Cytoeskeleton
202274_at Actin,  2, smooth muscle, enteric ACTG2 0.48 Cytoeskeleton
203180_at Aldehyde dehydrogenase 1 family, member A3 ALDH1A3 0.48 Aldehyde detoxification
222168_at Aldehyde dehydrogenase 1 family, member A3 ALDH1A3 0.22 Aldehyde detoxification
202357_s_at B-factor, properdin CFB 0.60 Complement activation
210916_s_at CD44 antigen (homing function and Indian blood group system) CD44 0.60 Hyaluronic acid binding
218182_s_at Claudin 1 CLDN1 0.51 Cell adhesion
204619_s_at Chondroitin sulfate proteoglycan 2 (versican) CSPG2 0.60 Hyaluronic acid binding
204620_s_at Chondroitin sulfate proteoglycan 2 (versican) CSPG2 0.51 Hyaluronic acid binding
211571_s_at Chondroitin sulfate proteoglycan 2 (versican) CSPG2 0.43 Hyaluronic acid binding
215646_s_at Chondroitin sulfate proteoglycan 2 (versican) CSPG2 0.48 Hyaluronic acid binding
221731_x_at Chondroitin sulfate proteoglycan 2 (versican) CSPG2 0.47 Hyaluronic acid binding
209395_at Chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 0.51 Sugar binding
209396_s_at Chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 0.42 Sugar binding
204602_at Dickkopf homolog 1 (Xenopus laevis) DKK1 0.42 Wnt signaling pathway
214511_x_at Fc fragment of IgG, high affinity Ia, receptor for (CD64) FCGR1A 0.59 Immune response
216950_s_at Fc fragment of IgG, high affinity Ia, receptor for (CD64) FCGR1A 0.62 Immune response
204419_x_at Hemoglobin,  A HBG1 0.51 Heme binding
203290_at Major histocompatibility complex, class II, DQ  1 HLA-DQA1 0.60 Immune response
209823_x_at Major histocompatibility complex, class II, DQ  1 HLA-DQB1 0.62 Immune response
221491_x_at Major histocompatibility complex, class II, DR  3 HLA-DRB3 0.43 Immune response
216207_x_at Immunoglobulin  constant IGKC 0.61 Immune response
214669_x_at Immunoglobulin  light chain mRNA, partial cds IGKV 0.55 Immune response
214677_x_at Immunoglobulin lambda joining 3 IGLJ3 0.64 Immune response
217148_x_at Immunoglobulin lambda joining 3 IGLJ3 0.56 Immune response
214777_at Immunoglobulin  light chain VKJ region mRNA IGLV 0.40 Immune response
216576_x_at Clone H10 anti-HLA-A2/A28 immunoglobulin light chain IGLV 0.44 Immune response
215176_x_at Partial mRNA for immunoglobulin light chain variable region IGLV 0.41 Immune response
222379_at Potassium voltage-gated channel, Isk-related family, member 4 KCNE4 0.58 Potassium ion transport
201496_x_at Myosin, heavy polypeptide 11, smooth muscle MYH11 0.38 Cytoeskeleton
201497_x_at Myosin, heavy polypeptide 11, smooth muscle MYH11 0.44 Cytoeskeleton
207961_x_at Myosin, heavy polypeptide 11, smooth muscle MYH11 0.50 Cytoeskeleton
205729_at Oncostatin M receptor OSMR 0.58 Cell proliferation
204939_s_at Phospholamban PLN 0.55 Calcium ion transport
204338_s_at Regulator of G-protein signaling 4 RGS4 0.43 Signal transduction
201645_at Tenascin C (hexabrachion) TNC 0.47 Cell adhesion
Fold change values were obtained by the SAM test.
FIG. 1. Comparison of gene expression by anal-
yses of microarray and RT-qPCR for 12 genes with
altered expression in PCOS patients compared
with nonhyperandrogenic women. Data are pre-
sented as fold change values from significance
analysis of microarrays and Ct methods.
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genes, appeared together in the same cluster, which gave us
an estimation of the reliability of the expression patterns
found.
Assuming that coexpressed genes may be coregulated, the
TransFAT tool was used to search for common cis-regulatory
elements. As shown in Fig. 2, we found some significant
associations between putative TFBSs and groups of coex-
pressed genes. We considered only those TFBSs that are
significantly overrepresented in most of the genes from a
particular gene cluster. A significant overrepresentation of
TFBSs previously involved in the pathogenesis of type 2
diabetes was found, including hepatic nuclear factor 4
(HNF4), forkhead box I, and forkhead box A2 (FOXA2) (26,
27). Several gene clusters manifested overrepresentation of
transcriptional effectors of Wnt/-catenin signaling path-
way, such as TCF4 in cluster B, or lymphoid enhancer-bind-
ing factor 1 in cluster J. We have also observed significant
overrepresentation of myelocytomatosis viral oncogene ho-
molog binding sites for all three genes in cluster D and for
a very homogeneous subgroup of genes from cluster F.
Discussion
Our present results revealed abnormal expression in
omental adipose tissue of genes encoding certain compo-
nents of several biological pathways, described herein, that
appear to be specific of PCOS because patients and nonhy-
perandrogenic controls presented with metabolic comorbidi-
ties with similar frequencies.
Abnormalities in insulin signaling pathway
Several genes involved in insulin resistance signaling
pathway presented altered expression in the omental adi-
pose tissue from our PCOS patients, in conceptual agreement
with the defective in vitro insulin-mediated glucose uptake
by PCOS adipocytes reported earlier (28, 29).
Overexpression of ENPP1 (also termed PC-1) might con-
tribute to the defective insulin signaling in PCOS patients,
because ENPP1 is a negative regulator of insulin receptor
tyrosine kinase activity and interacts with the insulin recep-
tor (IR) -subunit leading to inhibition of its -subunit (30).
Accordingly, increased expression of ENPP1 in adipose tis-
sue and muscle is associated with reduced insulin action in
nondiabetic insulin-resistant subjects (31). However, it
should be highlighted that the search for association with
genomic variation within ENPP1 in PCOS patients has
yielded conflicting results (32, 33).
Overexpression of PI3KR1, encoding for the regulatory
p85 subunit of phosphatydylinositol-3-kinase, could be in-
volved in the development of insulin resistance in our PCOS
patients. Mice lacking p85 have improved sensitivity to
insulin (34), and an increase in p85 expression without
changes in that of the catalytic subunit of phosphatydyli-
nositol-3-kinase leads to a reduced insulin sensitivity in skel-
etal muscle from insulin-resistant individuals (35).
The actin cytoskeleton is essential in regulating the traffic
of the glucose transporter 4 vesicles to the plasma membrane.
Several of the genes dysregulated in our study might con-
tribute to insulin resistance by interfering with this mecha-
nism, including the overexpression of RHOQ, PKN2, and
TABLE 4. List of the genes showing differential expression in omental fat of PCOS patients that contained putative androgen response
elements in their promoter regions
Gene Matrix similarity Sequencea Strand Matrix
Up-regulated genes
ALOX15 0.91 accccacctgctGTTCtct  V$GREF/ARE0.2
ARTS-1 0.91 ctttcactttcgGTCCtgg  V$GREF/ARE0.2
FLJ14054 0.9 cgcaagctgcctGTCCcag  V$GREF/ARE0.2
FLRT2 0.93 taatagcatgatGTCCttt  V$GREF/ARE0.2
LEP 0.9 gaaatccttgatGTCCctc  V$GREF/ARE0.2
LRAP 0.96 ctagtacttactGTACtag  V$GREF/ARE0.2
LRAP 0.99 ctttcactttctGTTCtaa  V$GREF/ARE0.2
PCYOX1 0.9 gaggccttacaGTTGtcg  V$GREF/ARE0.2
PIK3R1 0.9 ggcatgcgtgatGTCCtac  V$GREF/ARE0.2
PIK3R1 0.97 attggactgcctGTTCtag  V$GREF/ARE0.2
PIK3R1 0.89 ttgtggctctgtGTACtct  V$GREF/ARE0.2
SCD 0.96 cgcacgcatcctGTTCagg  V$GREF/ARE0.2
SYNC 0.94 gatggacttgcGTACctc  V$GREF/ARE0.2
TCF4 0.9 taaaaacttacaGTGCtgg  V$GREF/ARE0.2
TGFBR3 0.91 tcccaactccatGTCCtca  V$GREF/ARE0.2
TGFBR3 0.91 gaagggcctcctGTGCtct  V$GREF/ARE0.2
UPK3B 0.81 ccggagcatggTGTTgtgt  V$GREF/ARE0.1
Down-regulated genes
ACTA2 0.93 ttctcccatgctGTTCtca  V$GREF/ARE0.2
ACTA2 0.94 ctgccctttctGTTCtca  V$GREF/ARE0.2
CD44 0.9 atctttccttaGTCCttc  V$GREF/ARE0.2
FCGR1A 0.83 caagaaccacaTGTTgtct  V$GREF/ARE0.1
MYH11 0.9 ctgagacttggtGTCCata  V$GREF/ARE0.2
PLN 0.89 cattaacactttGTGCttc  V$GREF/ARE0.2
The search for androgen response elements was conducted using the MatInspector software (23) using the V$ARE0.01 and V$ARE0.02
matrixes contained in the MatBase version 6.1 library. Matrix similarity values above 0.80 are considered optimal, as perfect matches result
in values of 1.00.
a Uppercase letters represent core sequence.
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EBF2 (36–38) and the underexpression of two isoforms of
actin (ACTG2 and ACTA2) and one isoform of myosin
(MYH11). Moreover, the genes encoding MYH11, ACTG2,
and ACTA2 contain putative binding sites for the FOXA2
transcription factor (Fig. 2). Considering that the compen-
satory hyperinsulinemia attributable to insulin resistance
may induce insulin-mediated phosphorylation of FOXA2,
resulting in its nuclear exclusion and inactivation of its tran-
scriptional activity (39), we speculate that inhibition of
FOXA2 activity in PCOS might be related to the decreased
expression of the cytoskeleton proteins found in our series,
closing a vicious circle of insulin resistance, hyperinsulin-
emia, decreased glucose transporter 4 translocation into the
cell membrane, and further insulin resistance. Yet also, PKN2
encodes a serine/threonine kinase and might be involved in
the serine phosphorylation of the IR and IR substrate pro-
teins that have been proposed to impair insulin action in
PCOS (40–42).
Furthermore, RHOQ, EBF2, and PKN2 share the same
pattern of expression and present the same putative TFBS for
the hepatic nuclear factor 4 transcription factor previously
related to type 2 diabetes (26), suggesting a common in-
volvement of these genes in the mechanism of insulin resis-
tance in omental adipose tissue in PCOS.
Abnormalities in genes related to lipid metabolism
PDE3B, which encodes the major phosphodiesterase iso-
form in adipocytes and plays a pivotal role in the antilipolytic
action of insulin, and NPR3, encoding the natriuretic peptide
receptor C, which might decrease the lipolytic effect induced
by natriuretic peptides when activated (43), are overex-
pressed in our PCOS patients. These antilipolytic genes
might represent a compensatory mechanism against in-
creased catecholamine-induced lipolysis, which increases
the release of free fatty acids favoring insulin resistance,
observed in visceral fat cells from PCOS women (44).
Yet also, lipogenic enzymes such as SCD and ALOX15, a
TABLE 5. GO terms differentially represented in PCOS-dysregulated genes
GO Term Founda Totalb 2 P value
PCOS up-regulated processes
GO biological process
Nitric oxide biosynthesis 2 19 90.86 0.001
Response to toxin 2 22 77.95 0.001
Xenobiotic metabolism 2 55 28.93 0.001
Response to chemical substance 3 314 7.73 0.013
Fatty acid biosynthesis 2 80 18.76 0.002
Electron transport 2 457 4 0.021
GO molecular function
Cytochrome b5 reductase 2 9 198.1 0.001
NAD(P)H dehydrogenase (quinone) activity 2 50 450.0 0.001
Membrane alanyl aminopeptidase 2 20 87.0 0.001
Protein binding, bridging 2 109 13.0 0.001
Iron ion binding 2 94 15.6 0.001
Oxidoreductase activity 6 815 10.4 0.001
Receptor signaling protein activity 2 261 3.6 0.001
Extracellular matrix structural component 2 151 8.4 0.001
Growth factor activity 2 246 4.0 0.013
GO cellular component
Extracellular space 4 437 7.9 0.006
Extracellular matrix 4 494 6.4 0.007
Membrane 17 5839 1.3 0.047
PCOS down-regulated processes
GO biological process
Cell-cell adhesion 6 248 5.0 0.001
Cell recognition 5 27 476.7 0.001
Antigen presentation, via MHC class II 9 33 137.45 0.001
Immune response 7 1144 11.47 0.001
Development 11 2805 7.25 0.001
GO molecular function
Hyaluronic acid binding 6 32 602.3 0.001
IgG binding 2 10 105.02 0.001
MHC class II receptor activity 3 36 130.58 0.001
Sugar binding 7 189 129 0.001
Motor activity 5 203 58.19 0.001
Actin binding 3 377 7.87 0.001
Calcium ion binding 5 879 7.5 0.001
GO cellular component
Extracellular matrix 8 494 6.4 0.001
Actin filament 2 37 56.0 0.047
Only GO categories with FDR-adjusted P value  0.05 in 2 test were considered as significantly over- or underrepresented between genes
with altered expression in PCOS compared with nonhyperandrogenic samples. NAD(P)H, Nicotinamide adenine dinucleotide (phosphate); MHC,
major histocompatibility class.
a Number of dysregulated probe sets related to the GO term.
b Number of probe sets in the HG-U133A chip related to the GO term.
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lipoxygenase, were overexpressed in PCOS omental fat, pos-
sibly contributing to insulin resistance and, because lipoxy-
genases catalyze the oxidation of several fatty acids leading
to different oxidized lipids with inflammatory functions as
leukotrienes, to the chronic inflammatory milieu of PCOS. In
conceptual agreement, scd1/ knockout mice show im-
proved insulin signaling in adipose tissue and skeletal mus-
cle (45) and inhibition of lipoxygenases improves insulin
action in rat models of insulin resistance and type 2 diabetes
(46).
Abnormalities in genes related to the metabolic syndrome
The expression of HSD11B1 is increased in the omental
tissue of our PCOS patients. This gene encodes for type 1
11-hydroxysteroid-dehydrogenase, which catalyzes the
conversion of inactive cortisone into active cortisol. By in-
creasing cortisol levels in adipose tissue, increased HSD11B1
expression has been proposed to play a role in insulin-re-
sistant disorders such as the metabolic syndrome and PCOS
(47). Conflicting results have been reported regarding the
involvement of common polymorphisms in HSD11B1 in the
pathogenesis of PCOS (48, 49), suggesting that HSD11B1
overexpression might not be directly related to gene variants.
The overexpression of the leptin gene in omental adipose
tissue from our PCOS patients may be secondary to the
hyperinsulinemia and putatively increased local cortisol con-
centrations described (50), contributing to the increase in
serum leptin levels in PCOS patients reported in some pre-
vious studies (51).
Evidence for altered oxidative stress processes
Increased oxidant stress occurs in insulin-resistant pro-
cesses caused by hyperglycemia and elevated free fatty acids,
resulting in the generation of reactive oxygen species. Ex-
aggerated generation of the latter in response to hypergly-
cemia has been demonstrated in PCOS (52), together with
augmentation of oxidant status and a moderated increase in
some antioxidants (53). We have found overexpression of
genes involved in oxidative stress and toxicity processes such
as NQO1, GSTM3, PCYOX1, ALOX15, and DNAJB14 and
underexpression of ALDH1A3. The altered expression of
genes involved in depleting (GSTM3, NQO1, ALDH1A3)
and/or generating toxic products (PCYOX1) reflect the in-
duction or repression of biological pathways as compensa-
tory mechanisms to reduce the increased oxidant stress in
PCOS adipocytes.
Abnormalities in the Wnt-signaling pathway
DKK1, a negative regulator of this pathway, is underex-
pressed, and the TCF4 gene, which encodes for a Wnt tran-
scriptional effector, is overexpressed in PCOS. We also iden-
FIG. 2. Hierarchical average linkage
clustering of dysregulated genes be-
tween PCOS (P1–8) and control (C1–7)
omental adipose samples. Genes are
grouped according to the similarity of
their expression patterns across all
samples, using the Pearson’s correla-
tion as metric distance. The data set
includes 78 Affymetrix probe sets pre-
viously selected as significantly over- or
underexpressed in PCOS samples as
described in Results. Each row repre-
sents a single probe set, and each col-
umn represents an experimental sam-
ple. Each cell in the matrix represents
the log2 ratio of the abundance of a tran-
script to the mean abundance across all
experiments. Increasing green intensi-
ties denote genes that decrease in ex-
pression, and increasing red intensities
denote genes that increase in expres-
sion in PCOS samples compared with
control samples. Colored bars (A–J) in-
dicate the gene clusters obtained. On
the right side of the figure, putative TF-
BSs with significant overrepresenta-
tion in each set of coexpressed genes are
shown (P  0.05 in Fisher’s test). We
have considered only TFBSs present in
a high percentage of the genes (as in-
dicated in “% genes” column). a Not sig-
nificant (P  0.06).
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tified several groups of coexpressed genes showing a
significant overrepresentation for putative TFBSs of this
pathway (Fig. 2). Wnt signaling is involved in gender dif-
ferentiation, folliculogenesis, and ovulation (54), as well as in
adipogenesis (55). We hypothesize that the Wnt/-catenin
signaling pathway could be disturbed in PCOS adipose tis-
sue, as has been shown for the ovary in previous PCOS gene
expression studies (56, 57).
Immunological function
The expression of various genes belonging to the immune
system, such as class II major histocompatibility complex
molecules, several IgG chains, the BF complement factor,
FCGR1A, and ARST-1, showed altered expression patterns
in PCOS patients. This particular result might be related to
differences in the accumulation of macrophages in the adi-
pose tissue during the development of obesity, yet a previous
study using microarray analysis reported a similar pattern of
gene dysregulation in the ovaries of PCOS women (57).
Whether these findings are related to the proinflammatory
background contributing to insulin resistance and PCOS re-
main to be established.
Limitations
The small sample size analyzed possibly contributed to the
lack of statistically significant differences in indexes of in-
sulin resistance between patients and controls and explained
why we could not match a subgroup of PCOS patients and
controls for insulin resistance to delineate with precision the
influence of hyperandrogenism on gene expression. There-
fore, we cannot conclude whether the dysregulation of the
expression of some of the genes described is a direct conse-
quence of androgen excess on adipose tissue or a primary
omental defect that could influence the pathophysiology of
hyperandrogenism in PCOS patients. Also, it should be high-
lighted that the present results were obtained in women with
morbid obesity and cannot be extrapolated to women pre-
senting with milder grades of obesity.
Summary and conclusions
Our present results based on microarray analysis revealed
differences in the expression pattern of 63 genes, supported
by several normalization and statistical approaches, and by
the use of RT-qPCR.
Of note, the genes dysregulated in PCOS omental fat are
not only restricted to those involved in insulin signaling and
resistance but also include other functional pathways related
to, among others, Wnt signaling, inflammation, immune
function, and oxidative stress.
The involvement of several biological pathways suggests
that the participation of visceral adipose tissue in the patho-
genesis of PCOS and its metabolic complications is not lim-
ited to the well-known influence of obesity on insulin resis-
tance and the contribution of hyperinsulinism to ovarian
hyperandrogenism, yet actually involves several different
pathogenic mechanisms and biological pathways.
Although the use of human samples in microarray studies
is limited by the high variability among individuals resulting
from the genetic heterogeneity of human beings, and al-
though gene expression analyses should be complemented
by functional studies and/or proteomic techniques currently
ongoing, our present results demonstrate up- and down-
regulation of genes encoding molecules previously proposed
to influence the pathogenesis of PCOS, insulin resistance,
and the metabolic syndrome and also a considerable number
of dysregulated genes that, from now on, based on our find-
ings, should be considered as candidate genes for the etiol-
ogy of PCOS.
Hopefully, the complete characterization of these genes,
their proteins, and the biological pathways differentially in-
volved in the relationship between visceral obesity and
PCOS will contribute to a better understanding of the patho-
physiology of this prevalent disorder.
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